While VEGF-A has been identified as playing a key role in the promotion of choroidal neovascularization in wet AMD, a study done on patients receiving anti-VEGFA treatment demonstrated significant increase in levels of other angiogenic biomarkers including VEGF-C and angiopoietin-2 [44]. The gene discussed is ANGPT2; the disease is wet macular degeneration.